MA56708B1 - Dérivés d'alcool utilisés en tant qu'ouvreurs des canaux potassiques kv7 - Google Patents

Dérivés d'alcool utilisés en tant qu'ouvreurs des canaux potassiques kv7

Info

Publication number
MA56708B1
MA56708B1 MA56708A MA56708A MA56708B1 MA 56708 B1 MA56708 B1 MA 56708B1 MA 56708 A MA56708 A MA 56708A MA 56708 A MA56708 A MA 56708A MA 56708 B1 MA56708 B1 MA 56708B1
Authority
MA
Morocco
Prior art keywords
potassium channel
alcohol derivatives
derivatives used
channel openers
compounds
Prior art date
Application number
MA56708A
Other languages
English (en)
French (fr)
Inventor
Mario Rottländer
Anette Graven Sams
Xiaofang Wang
Debasis DAS
Jian Hong
Shu Hui Chen
Krestian Larsen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of MA56708B1 publication Critical patent/MA56708B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
MA56708A 2019-08-02 2020-07-30 Dérivés d'alcool utilisés en tant qu'ouvreurs des canaux potassiques kv7 MA56708B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19189750 2019-08-02
CN201910734123 2019-08-09
EP19191887 2019-08-15
PCT/EP2020/071520 WO2021023617A1 (en) 2019-08-02 2020-07-30 Alcohol derivatives as kv7 potassium channel openers
EP20749879.1A EP4007634B1 (en) 2019-08-02 2020-07-30 Alcohol derivatives as kv7 potassium channel openers

Publications (1)

Publication Number Publication Date
MA56708B1 true MA56708B1 (fr) 2024-12-31

Family

ID=71894829

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56708A MA56708B1 (fr) 2019-08-02 2020-07-30 Dérivés d'alcool utilisés en tant qu'ouvreurs des canaux potassiques kv7

Country Status (27)

Country Link
EP (2) EP4461725A3 (enExample)
JP (2) JP7720829B2 (enExample)
KR (1) KR102957984B1 (enExample)
CN (1) CN114206830B (enExample)
AU (1) AU2020325517B2 (enExample)
BR (1) BR112021006324A2 (enExample)
CA (1) CA3148719A1 (enExample)
CL (1) CL2022000221A1 (enExample)
CO (1) CO2022000080A2 (enExample)
CR (1) CR20220028A (enExample)
DO (1) DOP2022000026A (enExample)
EC (1) ECSP22008993A (enExample)
ES (1) ES2989376T3 (enExample)
GE (2) GEAP202415862A (enExample)
HR (1) HRP20241444T1 (enExample)
HU (1) HUE069310T2 (enExample)
IL (1) IL290193B2 (enExample)
JO (1) JOP20220017A1 (enExample)
MA (1) MA56708B1 (enExample)
MX (1) MX2022001063A (enExample)
PE (1) PE20220345A1 (enExample)
PH (1) PH12022550192A1 (enExample)
PL (1) PL4007634T3 (enExample)
RS (1) RS66130B1 (enExample)
SM (1) SMT202400445T1 (enExample)
WO (1) WO2021023617A1 (enExample)
ZA (1) ZA202109598B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2989376T3 (es) * 2019-08-02 2024-11-26 H Lundbeck As Derivados de alcohol como abridores del canal de potasio Kv7
AU2024310446A1 (en) * 2023-06-27 2026-01-22 Saniona A/S Kv7 modulators
WO2026132415A1 (en) * 2024-12-20 2026-06-25 Saniona A/S Kv7 modulators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893858B2 (en) 2000-05-26 2005-05-17 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20090118285A1 (en) 2006-02-07 2009-05-07 H. Lundbeck A/S Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
WO2007104717A1 (en) * 2006-03-15 2007-09-20 Neurosearch A/S Quinazolinones and their use as potassium channels activators
CN101790374A (zh) 2007-08-01 2010-07-28 H.隆德贝克有限公司 Kcnq钾通道开放剂用于减轻多巴胺能系统受到干扰的障碍或病症的症状或治疗这种障碍或病症的用途
TW201024286A (en) * 2008-11-27 2010-07-01 Neurosearch As Novel compounds
EP2928860A1 (en) * 2012-12-10 2015-10-14 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
ES2749103T3 (es) * 2014-09-12 2020-03-19 Knopp Biosciences Llc Benzoimidazol-1,2-ilamidas como activadores del canal Kv7
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
CN105663136A (zh) * 2016-01-15 2016-06-15 河北中医学院 法舒地尔作为制备选择性Kv7离子通道激活剂药物的应用
US10590067B2 (en) * 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
ES3032221T3 (en) * 2018-02-20 2025-07-16 H Lundbeck As Alcohol derivatives as kv7 potassium channel openers
ES2989376T3 (es) * 2019-08-02 2024-11-26 H Lundbeck As Derivados de alcohol como abridores del canal de potasio Kv7
US12508239B2 (en) * 2019-08-02 2025-12-30 H. Lundbeck A/S Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures

Also Published As

Publication number Publication date
RS66130B1 (sr) 2024-11-29
EP4007634C0 (en) 2024-10-02
MX2022001063A (es) 2022-02-14
ES2989376T3 (es) 2024-11-26
HUE069310T2 (hu) 2025-02-28
CN114206830B (zh) 2024-07-30
EP4461725A3 (en) 2025-01-15
CL2022000221A1 (es) 2022-10-07
KR20220041084A (ko) 2022-03-31
JP7897992B2 (ja) 2026-07-30
JOP20220017A1 (ar) 2023-01-30
GEP20247629B (en) 2024-06-10
BR112021006324A2 (pt) 2022-02-15
CO2022000080A2 (es) 2022-01-17
DOP2022000026A (es) 2022-03-31
PH12022550192A1 (en) 2022-11-21
CR20220028A (es) 2022-03-02
JP7720829B2 (ja) 2025-08-08
IL290193B1 (en) 2024-08-01
CN114206830A (zh) 2022-03-18
ECSP22008993A (es) 2022-03-31
ZA202109598B (en) 2024-04-24
AU2020325517A1 (en) 2022-02-24
KR102957984B1 (ko) 2026-04-27
EP4461725A2 (en) 2024-11-13
GEAP202415862A (en) 2024-01-25
IL290193A (en) 2022-03-01
SMT202400445T1 (it) 2024-11-15
JP2022543203A (ja) 2022-10-11
PL4007634T3 (pl) 2024-11-25
AU2020325517B2 (en) 2025-08-28
IL290193B2 (en) 2024-12-01
WO2021023617A1 (en) 2021-02-11
JP2025160211A (ja) 2025-10-22
PE20220345A1 (es) 2022-03-14
CA3148719A1 (en) 2021-02-11
EP4007634B1 (en) 2024-10-02
EP4007634A1 (en) 2022-06-08
HRP20241444T1 (hr) 2024-12-20

Similar Documents

Publication Publication Date Title
MA51881B1 (fr) Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA53861B1 (fr) Modulateurs de promédicaments de la voie de réponse intégrée au stress
MA53455B1 (fr) Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA51669B1 (fr) Modulateurs de tmem16a
MA44851A (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA54133B1 (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
MA47392B1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA50398B1 (fr) Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
MA45843B1 (fr) Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)
MA59447B1 (fr) Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6 pour le traitement du cancer
JOP20220017A1 (ar) مشتقات كحول على هيئة عوامل فتح قناة بوتاسيوم Kv7
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA52375A1 (fr) Inhibiteurs de cdk8/19
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA68743B1 (fr) Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa
MA60100B1 (fr) Dérivés de tétrazole utiles en tant qu'inhibiteurs de trpa1
MA60099B1 (fr) Dérivés de tétrazole utiles en tant qu'inhibiteurs de trpa1
ES2152648T3 (es) Difenilestilbenos como profarmacos inhibidores de la cox-2.
MA60976B1 (fr) Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamine
WO2022129047A3 (en) Modulators of the nmda receptor